Cameron E, Pauling L
Proc Natl Acad Sci U S A. 1976 Oct;73(10):3685-9. doi: 10.1073/pnas.73.10.3685.
Ascorbic acid metabolism is associated with a number of mechanisms known to be involved in host resistance to malignant disease. Cancer patients are significantly depleted of ascorbic acid, and in our opinion this demonstrable biochemical characteristic indicates a substantially increased requirement and utilization of this substance to potentiate these various host resistance factors. The results of a clinical trial are presented in which 100 terminal cancer patients were given supplemental ascorbate as part of their routine management. Their progress is compared to that of 1000 similar patients treated identically, but who received no supplemental ascorbate. The mean survival time is more than 4.2 times as great for the ascorbate subjects (more than 210 days) as for the controls (50 days). Analysis of the survival-time curves indicates that deaths occur for about 90% of the ascorbate-treated patients at one-third the rate for the controls and that the other 10% have a much greater survival time, averaging more than 20 times that for the controls. The results clearly indicate that this simple and safe form of medication is of definite value in the treatment of patients with advanced cancer.
抗坏血酸代谢与许多已知参与宿主对恶性疾病抵抗力的机制相关。癌症患者体内的抗坏血酸显著减少，在我们看来，这种明显的生化特征表明该物质的需求量和利用率大幅增加，以增强这些不同的宿主抵抗因子。本文展示了一项临床试验的结果，其中100名晚期癌症患者在常规治疗中补充了抗坏血酸盐。将他们的病情进展与1000名接受相同治疗但未补充抗坏血酸盐的类似患者进行比较。抗坏血酸盐组患者的平均生存时间（超过210天）是对照组（50天）的4.2倍多。对生存时间曲线的分析表明，约90%接受抗坏血酸盐治疗的患者死亡速度仅为对照组的三分之一，另外10%的患者生存时间长得多，平均超过对照组的20倍。结果清楚地表明，这种简单且安全的药物治疗方式对晚期癌症患者的治疗具有明确价值。
